The effect of Chinese herbal medicine Shugan Wendan Decoction for the treatment of H-type essential hypertension: a ranodmized controlled trial.

Phase 4

• Conditions: H-type essential hypertension

• Registration Number: ITMCTR2000003480
• Lead Sponsor: Guangdong Provincial Hospital of Traditional Chinese Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Blood pressure >= 130/80 mmHg and/or has been diagnosed with high blood pressure, and normal blood pressure after treatment (the treatment plan is Valsartan capsule 80mg qd), and Hcy >= 10µmol/L;
2. Comply with phlegm and blood stasis syndrome, and liver stagnation syndrome-those with the following 3 main syndromes or 2 main syndromes plus 2 or more secondary syndromes can be diagnosed:
Main symptoms: (1) limbs are heavy and full of abdominal distension; (2) Tingling, pain has a fixed place; (3) Emotional depression or irritability, irritability, goodness and rest;
Secondary evidence: (1)flank pain; (2) nausea and vomiting; (3) veins and ecchymosis (lips, gums, dark purple nails, red skin on the muscle surface);(4) The tongue is greasy or the tongue is dark purple or has ecchymosis, petechiae, and thick tongue veins; (5) pulse string or pulse string; (6) local sensory disturbance.
3. The age is 30~75 years old;
4. Those who agree to cooperate with the collection of data and improve relevant inspections;
5. Those who voluntarily signed informed consent.

Exclusion Criteria

1. Complicated with severe cardiovascular and cerebrovascular diseases (such as cardiac insufficiency, acute myocardial infarction, cerebral infarction, cerebral hemorrhage, etc.), liver and kidney dysfunction, mental disorders and other diseases;
2. Those who are unwilling to cooperate with data collection and blood drawing;
3. Women during pregnancy or lactation;
4. Patients who have used other antihypertensive drugs other than valsartan capsules or have high blood lipid levels and need to use lipid-lowering drugs;
5. Other circumstances that the researcher thinks are not suitable for participating in this research.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Homocysteine;blood pressure;